Eli Lilly and Company (LLY) : During the past 4 weeks, traders have been relatively bearish on Eli Lilly and Company (LLY), hence the stock is down -5.41% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -0.38% relative to the S&P 500. The 4-week change in the price of the stock is -5.61% and the stock has fallen -1.04% in the past 1 week.
For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 2.82% and the fifty day Moving Average is 0.88%. Eli Lilly and Company is up 5% in the last three month period. Year-to-Date the stock performance stands at -5.27%.
Eli Lilly and Company (LLY) : The consensus price target for Eli Lilly and Company (LLY) is $95.73 for the short term with a standard deviation of $17.14. The most optimist securities analyst among the 11 who monitor the stock believes that the stock can reach $116, however, the pessimist price target for the company is $55.
Eli Lilly and Company (NYSE:LLY): stock turned positive on Friday. Though the stock opened at $78.05, the bulls momentum made the stock top out at $78.82 level for the day. The stock recorded a low of $77.84 and closed the trading day at $78.24, in the green by 0.29%. The total traded volume for the day was 2,602,317. The stock had closed at $78.01 in the previous days trading.
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers, develops, manufactures and market products in two segments: human pharmaceutical products and animal health products. The Companys products are sold in approximately 120 countries. The Companys human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Companys Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States, Puerto Rico and 11 other countries. Its products include endocrinology products, neuroscience products, oncology products, cardiovascular products, products for food animals, products for companion animals and Novartis AH products.